Dive Insight:

Ethical questions continue to surround president-elect Donald Trump's HHS Secretary nomination. Since the announcement, Price's healthcare stock portfolio has seen its share of the limelight as new reports continue to question whether Price used his insider knowledge appropriately.

While Price's actions were not illegal, his stock portfolio continues to add to his narrative as his HHS hearings draw near.This could have big implications if it ends up delaying his confirmation. Trump has recently stated he wants to replace the ACA quickly after Price is confirmed. If that confirmation drags on (or if the nomination needs to be changed), that could drastically change the ACA repeal-and-replace timeline.